[Clinical observation of posttransplant lymphoproliferative disorder in a single center].

To analyze the clinical characteristics of post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) lymphoproliferative disorders and to explore the clinical guidance provided by the latest nomenclature for post-transplant lymphoproliferative disorders (PTLD) in the 2022 World Health Organization Classification of Hematologic and Lymphoid Tumors (WHO-HAEM5). A retrospective analysis was conducted on the clinical data of 35 patients diagnosed with PTLD after allo-HSCT at the Department of Hematology, Fifth Medical Center, Chinese PLA General Hospital, from January 1, 2016, to December 15, 2024. Among these, 11 cases were clinically diagnosed, and 24 cases were pathologically confirmed. The 24 pathologically confirmed PTLD cases were renamed according to the latest WHO-HAEM5 nomenclature. Monomorphic PTLD, corresponding to the lymphoma subtype of PTLD, exhibited the poorest prognosis with a over survival rate of only 54.5% (6/11). All deceased patients had severe aplastic anemia (SAA) as the primary disease; one death resulted from chemotherapy-related complications, while the remaining four died due to explosive PTLD progression. PTLD patients with SAA as the primary diagnosis exhibit poor prognosis, necessitating more aggressive clinical intervention strategies.